Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant Gram-negative pathogens.

@article{Czihal2012Api88IA,
  title={Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant Gram-negative pathogens.},
  author={Patricia Czihal and Daniel Knappe and Stefanie Fritsche and Michael Zahn and Nicole Berthold and Stefania Piantavigna and Uwe C. Mueller and Sylvia Van Dorpe and Nicole Herth and Annegret Binas and G. K{\"o}hler and Bart De Spiegeleer and Lisandra L Martin and Oliver Nolte and Norbert Str{\"a}ter and Gottfried Alber and Ralf Hoffmann},
  journal={ACS chemical biology},
  year={2012},
  volume={7 7},
  pages={1281-91}
}
The emergence of multiple-drug-resistant (MDR) bacterial pathogens in hospitals (nosocomial infections) presents a global threat of growing importance, especially for Gram-negative bacteria with extended spectrum β-lactamase (ESBL) or the novel New Delhi metallo-β-lactamase 1 (NDM-1) resistance. Starting from the antibacterial peptide apidaecin 1b, we have optimized the sequence to treat systemic infections with the most threatening human pathogens, such as Escherichia coli, Klebsiella… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
28 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…